Contacts:                                                                                                                                                                                                                 Media:
Gertrude Pfost                                                                                                                                                                                                        Barbara Lindheim
MicroBiome Therapeutics                                                                                                                                                                                    BLL Partners, LLC
(609) 216-1203                                                                                                                                                                                                       (212) 584-2276


—Learn More about MBT’s Gastrointestinal Microbiome Modulators at 17th Annual BIO CEO and Investor Conference—

Broomfield, CO – February 9, 2015 – MicroBiome TherapeuticsTM LLC, (MBT) today reported that the U.S. Patent and Trademark Office has issued a notice of allowance for the company’s patent application covering the use of glyceollin to treat diabetes and obesity. MBT is investigating glyceollins for the treatment of metabolic disorders, including diabetes and obesity, as well as their potential role in modulating the gastrointestinal microbiome. MBT also announced that it is participating in the One-on-One Partnering sessions of the 17th Annual BIO CEO and Investor Conference being held this week in New York City.

Glyceollin I, II and III are small molecule natural products made by soy plants under certain environmental conditions to help combat infectious organisms and other stressors. In animal studies, glyceollins have demonstrated activity in a number of human disease models, including breast and ovarian cancer, hyper-cholesterolemia and metabolic disorders.

“MBT researchers have been studying glyceollins for some time, and we are excited about their potential as novel agents for the treatment of diabetes and obesity,” said Steve Orndorff, PhD, CEO of MicroBiome Therapeutics. “We are encouraged too by the results of our recently completed animal studies assessing whether glyceollin can affect the regulation of blood glucose, and we look forward to reporting the findings in a peer-reviewed forum. We also plan to study glyceollins as part of our gastrointestinal microbiome modulator (GIMM) program, whose lead products, NM 504 and NM 505, have demonstrated positive results in pilot clinical studies in diabetes and prediabetes. With the broad claims of this new patent now assured, we intend to move ahead with this promising new approach to these conditions that adversely impact millions of people worldwide.”

U.S. Patent Application No.: 12/976,209, Title: Compositions and Methods for Treating Obesity and Diabetes, is expected to issue in the next few months.
The 17th Annual BIO CEO and Investor Conference is being held at The Waldorf Astoria in New York City, February 9-10, 2015. For more information about the BIO CEO One-on-One Partnering meetings, visit https://www.bio.org/node/3167/

About MicroBiome Therapeutics
MicroBiome Therapeutics LLC (MBT) is a clinical stage biotechnology company developing drug therapies for metabolic diseases that aim to improve health status by altering microbial populations and their environment in the GI tract. MBT’s gastrointestinal microbiome modulators (GIMMs) are designed to augment the growth of certain desirable bacterial strains and discourage the growth of others. MBT’s first GIMM, NM504, improved blood glucose levels in a clinical trial in prediabetes and Type 2 diabetes. GIMM NM505 is a reformulation of metformin incorporating microbiome modulators to increase the tolerability and utility of this first-line diabetes therapy. It also has demonstrated positive results in a proof-of-concept clinical study. For more information, visit mbiome.com.